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Abstract: Soft tissue sarcomas (STS) are a rare group of malignancies with multiple different subtypes. Close to half of intermediate 
or high grade STS develop metastatic disease. Treatment of recurrent/metastatic sarcomas is quite challenging with only a few drugs 
showing  measurable  benefits. Trabectedin  (ecteinascidin  743,  ET-743, Yondelis)  is  a  newly  developed  alkylating  agent  that  has 
shown significant broad spectrum potential as a single agent second line drug alone or in combination particularly in the treatment of 
liposarcomas and leiomyosarcomas. Clinical benefit rates seem to favor its use especially in pretreated patients with recurrent/metastatic 
disease. The drug is well tolerated in general but hepatotoxicity and hematologic side effects are common. Approved in Europe, the 
currently ongoing Phase III trials along with the already existing clinical evidence may provide enough data for the Food and Drug 
Administration for an approval in the US.
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Introduction
Soft  tissue  sarcomas  (STS)  are  a  rare  group  of 
diverse tumors, mostly mesenchymal in origin, and 
account for approximately 1% of adult   malignancies. 
Sarcomas can develop from multiple different tissues, 
with fat, vessels, nerves, bones, muscle and deep skin 
tissues being the most common site of origin. In 2010 
there were approximately 10,520 (STS) and 2,650 
(bone) new cases diagnosed in the US. This group 
of tumors was also responsible for 3,920 (STS) and 
1,460 (bone) deaths in the same year.1 They tend to 
occur with increasing frequency with age, but they 
also represent 7%–10% of childhood malignancies. 
They are also one of the leading causes of death in 
the  14–29  year  age  group.  The  number  of  newly 
  diagnosed cases has been relatively constant over the 
last 30 years.
STS  have  several  different  subtypes. The  exact 
number  of  newly  diagnosed Americans  with  each 
subtype  is  unknown,  secondary  to  the  difficulty 
  differentiating these tumors from each other and other 
types of malignancies. The overall numbers are likely 
underreported.  Close  to  half  of  STS  patients  with 
intermediate or high grade develop metastatic   disease. 
The majority of these patients are being treated with 
chemotherapy, but the 5-year survival remains only 
about 50%.2,3
The importance of differentiating the over 50 sub-
types  of  sarcomas  has  been  increasing  with  the 
discovery  of  new  drugs  and  improved  knowledge 
of molecular mechanisms.4 Genetic abnormalities in 
STS have also been getting increasing attention. The 
association of familial neurofibromatosis, NF1 gene 
and malignant peripheral nerve sheet tumors has been 
known for a while. Similarly, familial retinoblastoma 
has been known to be associated with inherited muta-
tions of retinoblastoma gene.4 Therapy for different 
subtypes of STS is evolving and differentiating.5
Therapy of recurrent inoperable or metastatic STS 
is  challenging. The  currently  used  drugs  and  drug 
combinations  only  have  marginal  proven  benefit. 
The response rate to doxorubicin is low (10%–30%) 
and with ifosfamide is higher, but without   survival 
advantage.2,3  The  response  rate  is  even  lower  in 
patients who already failed the first line agents. For 
leiomyosarcomas (LMS), gemcitabine with or without 
docetaxel is used for first or second line treatment. 
Dacarbazine (DTIC) also has activity in both LMS   
and  liposarcomas  (LPS).  Taxanes  particularly  in 
weekly administration are used for angiosarcomas. 
Many of these traditionally used drugs have significant 
and  cumulative  toxicities,  requiring  frequent  dose 
modifications or discontinuation of treatment.2
Trabectedin is the most extensively studied drug 
in patients with STS failing treatment with standard 
anthracycline  and  ifosfamide.6–8  While  trabectedin 
does not have proven benefits in all STS’s, there is 
reasonable evidence from Phase I and Phase II clinical 
trials to prove that it is a safe and effective treatment 
alternative  with  specific  efficacy  in  myxoid  LPS/
round cell sarcoma and LMS. The persistently high 
response rate in various studies is encouraging. In a 
cost-effectiveness analysis trabectedin was found to 
be a potentially cost effective treatment of metastatic 
STS patients with a previous history of treatment with 
standard drugs.9 The calculated cost-effectiveness of 
trabectedin was comparable or superior to many other 
cancer  drugs  used  today.  In  addition,  trabectedin 
  compared  to  end-stage  treatment  was  estimated 
to result in a 14 months of additional survival and 
9 to 10 months of additional quality-adjusted survival 
compared to end-stage treatment alone.
Trabectedin Development and Use  
in Metastatic Sarcomas
Mechanism of action, metabolism  
and pharmacokinetic profile
Trabectedin (ecteinascidin 743, ET-743, Yondelis) is 
derived from the Caribbean sea squirt Ecteinascidia 
turbinate (Fig. 1). Its main mode of action is as an 
alkylating  agent  against  deoxyribonucleic  acid 
(DNA). Unlike conventional alkylating agents which 
bind to the major groove of DNA and predominantly 
form crosslinks to the Guanine N7 or O6 position, 
trabectedin predominantly binds to the minor groove 
of  DNA  and  binds  to  the  Guanine  N2  position.10 
Additionally, cells deficient in transcription-coupled 
nucleotide excision repair, but not mismatch repair, 
appear much less sensitive to trabectedin than other 
alkylators.
Deficiencies in homologous recombination repair 
render the cell quite sensitive to the toxic effects of 
trabectedin,  thus  BRCA1/2  or  other    Fanconi  gene 
  deficiency would render the tumor cells   sensitive.11 
In  part,  this  corresponds  to  a  direct  binding  inter-
action with DNA and Rad13 in a complex. Due to Trabectedin treatment in advanced sarcomas
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changes in DNA structure, trabectedin can inhibit the 
  production of IL-6 and CCL2 from   tumor-associated 
  macrophages, which may also provide some of its 
anti-tumor  effect. Also  reported  are  more  specific 
inhibitions  of  fusion  proteins  such  as  FUS-CHOP 
or  EWS-CHOP  seen  in  MLS  and  in  EWS-FLI  in 
Ewing’s. Tumor cells having p53 mutations appear 
more   sensitive to trabectedin compared to those with 
wt p53.12 Preclinically, trabectedin appears additive or 
synergistic with doxorubicin in various sarcoma and 
breast lines, and with platinums in ovarian,   sarcoma 
and other cell lines. It inhibits MDR1 transcription and 
thus modulates P-glycoprotein mediated   resistance to 
other agents. Pharmacokinetics shows a mean termi-
nal half life (T1/2) of approximately 61 hours. It is 
heavily protein bound, and extensively metabolized 
by the liver, especially P450 3A4. Systemic clearance 
was approximately 19% higher when dexamethasone 
was coadministered. The area under the curve (AUC) 
is somewhat higher when administered over a 24 hour 
infusion, although the maximum plasma concentra-
tion of the drug (Cmax) is reduced, as more drug may 
be delivered when adjusting for toxicity.13
Clinical studies
Trabectedin  is  the  second  marine-derived  drug 
approved  for  treatment  of  cancer.  Trabectedin  has 
shown in vitro and in vivo activities in a   variety of 
human  malignancies:  STS,  breast  cancer,    ovarian 
  cancer and various other solid malignancies. Although 
broad  activity  is  observed  across  the    histologic 
subtypes  of  sarcoma,  activity  is  greatest  in  LPS 
  (especially myxoid LPS) and LMS.
Single agent (phase I)
The first phase 1 studies examining the antitumor 
effects  of  trabectedin  date  back  to  early  2000. 
  Twenty-nine pretreated for advanced STS and bone 
sarcoma were analyzed from a phase 1 clinical trial as 
well as compassionate use program.14 Every three to 
four-week treatment of 24 hour infusion was used in 
escalating doses. The most common toxicities were 
transaminitis,  neutropenia  and  thrombocytopenia. 
Ten patients had disease stabilization, two patients 
had  minor  response  and  four  patients  had  partial 
responses.  Median  duration  of  response  was  over 
10  months.  This  study  proved  that  trabectedin 
had  activity  in  highly  pretreated  STS  and  bone 
sarcomas.
Another phase one study from Europe compared 
every-three  week  infusion  of  escalating  doses 
of  trabectedin  over  1  and  3  hours.15  There  were 
72 adults included with a wide variety of primary 
tumors,  including  advanced  or  metastatic  STS. 
The  most  common  dose-limiting  toxicities  were 
fatigue,  neutropenia  and  thrombocytopenia  again. 
Hematologic  and  hepatic  toxicities  were  dose 
dependant and not cumulative. The pharmacokinetics 
was linear with 3 hour infusion. Antitumor activity 
was evaluated in 49 patients. Most responders had 
a  minor  response  (37%).  Nine  patients  had  stable 
disease for 6 or more cycles. The authors concluded 
that trabectedin can be safely administered in 1 and 
3 hour iv infusions and the maximum tolerated dose 
(MTD) can be increased by prolonging the duration of 
infusion without affecting the drug’s safety profile.
A recently published phase I dose escalating trial 
also determined the safety, tolerability, pharmacoki-
netics of trabectedin when given as 1-hour or 3-hour 
iv infusion for 3 consecutive weeks every 4 weeks.16 
Most treated patients had advanced STS with some 
patients being treated after   establishing a diagnosis of 
breast/ovarian cancer and   melanoma. Over 30 patients 
were treated in sequential cohorts of trabectedin on the 
1 and 3 hour schedules.   Neutropenia, transaminitis, 
fatigue  and  transient    creatinine  phosphokinase 
  elevation limited the MTD to 0.61 mg/m2 in the 1 hour 
schedule and to 0.58 mg/m2 in the 3 hour schedule. 
These  respective  MTD’s  were  recommended  for 
O OH
O
O O S
N
N
O O
O
HO
HO
NH O
Figure 1. Structure of trabectedin: (1′R,6R,6aR,7R,13S,14S,16R)-6′,8, 
14-trihydroxy-7′,9-dimethoxy-4,10,23-trimethyl-19-oxo-3′, 
4′,6,7,12,13,14,16-octahydrospiro[6,16-epithiopropanooxymethano)-
7,13-imino-6aH-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-
20,1′(2′H)-isoquinolin]-5-yl acetate.Gajdos and elias
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future clinical trials. Several patients had prolonged, 
stable disease.
Combination therapy (phase I)
Trabectedin was tested in combination trials based 
on in vitro studies showing synergy with doxorubicin 
and cisplatin in STS cells. A phase I study enrolled 
41 previously treated patients in an open-label multi-
center trial.17 Granulocyte colony stimulating factor 
(G-CSF) was added to the regimen after the first six 
patients were noted to have dose limiting neutropenia. 
Half of the patients had LPS. The maximum tolerated 
dose for trabectedin was 1.1 mg/m2 and for doxorubicin 
60 mg/m2. Grade 3/4 treatment related toxicity was 
quite high at 71% combined. Median progression free 
survival was 9.2 months with 33 patients maintaining 
stable disease.
Gemcitabine is a nucleoside analog with a wide 
variety of treatment indications: pancreas cancer, lung 
cancer, breast cancer and certain sarcomas. A phase I 
study enrolled 15 pre-treated patients who were treated 
with  weekly  trabectedin  and  gemcitabine  between   
2003 and 2005.18 The majority of patients had sarcoma 
or lung cancer. The major side effect was hepatotoxicity 
resulting  in  frequent  dose  adjustments.  Fatigue, 
nausea, vomiting neutropenia and anorexia were also 
common (27%–73%). Half of the patient maintained 
stable  disease  for  56–226  days.  In  conclusion  the 
study found a potentially manageable toxicity profile 
with a lower dose of trabectedin compared to single 
agent usage.
The few studies looking at the safety of trabectedin, 
in combination with other drugs, found that a lower 
dose  of  trabectedin  is  needed  in  combination  to 
maintain a manageable safety profile.
Safety profile of single agent
Demetri et al examined the safety of trabectedin in a 
phase II clinical trial.19 Most drug related side effects 
were grade 2. Only five percent of patients required 
hospitalization secondary to drug related side effects. 
Ninety-two percent of patients received trabectedin 
according to protocol. The most common grade 3/4 
drug  related  side  effects  were  fatigue,    nausea  and 
vomiting. Neutropenia and thrombocytopenia were 
the most common grade 3/4 hematologic side effects, 
but  they  were  transient  with  rapid  recovery.  Liver 
related grade 3/4 toxicities were mostly limited to 
transient elevation of AST and ALT with bilirubin 
being affected uncommonly. Death attributable to the 
drug was rather uncommon (3%).
A non-randomized phase II study by the   European 
Organization  for  the  Research  and  Treatment  of 
  Cancer  (EORTC)  analyzed  side  effect  profile  of 
trabectedin in 99 eligible patients.20 Dose reduction 
was necessary at least once in 31% of patients mostly 
secondary  to  nonhematologic  toxicities.  Toxicities 
were mainly hematologic and hepatic. Grade 3 or 4 
neutropenia  and  thrombocytopenia  were  the  most 
common  (53%/18%).  Sixteen  percent  of  patients 
experienced  grade  3  to  4  anemia.  Non-cumulative 
liver toxicities were grade 3/4 transient elevation of 
transaminases seen in 35%–45% of patients. Besides, 
42% and 63% had elevation of bilirubin and alkaline 
phosphatase. The treatment related mortality was 4%. 
There was a correlation between liver dysfunction and 
the toxicities leading to death. Elevated creatinine, 
diarrhea and vomiting occurred in 9%–21% of treated 
individuals,  while  fatigue  was  a  more  common 
complaint (62%).
A  non-randomized  multicenter  Phase  II  study 
from France examined the effects of trabectedin in 
54  preterated  patients  with  advanced  STS.21  Most 
patients had LMS (41%). A 24-hr iv infusion every 
3  weeks  was  used.  Patients  received  a  median 
of  3  cycles  of    trabectedin.  Reversible  grade  3/4 
transaminitis occurred in 50% of patients and grade 
3/4 neutropenia occurred in 61% of patients. The study 
also reported two   treatment related death.
A prospective phase II study from primarily US 
institutions  enrolled  36  pretreated  patients  to  be 
treated with a 24 hour continuous infusion at a dose of 
1500 ugm/m2 every three weeks.22 The predominant 
toxicities were neutropenia and self limited transamin-
itis. A total of 14% of the cycles had to be dose reduced, 
mostly for the above mentioned reasons. Thirty-five 
percent of the cycles had to be delayed for similar 
reasons.  The  frequency  of  Grade  3/4  hematologic 
toxicities  were  leucopenia  (43%)  and  neutropenia 
(34%). Severe thrombocytopenia occurred in 17% of 
the patients. Severe transaminitis was seen with grade 
3/4 elevations in 20%–26% (AST/ALT). Fatigue was 
common  (69%)  and  nausea  (15%)  vomiting  (6%) 
responded well to routine dexamethasone.
A similarly designed study but in chemo-  therapy 
naïve  patients  found  that  dose  reductions  were Trabectedin treatment in advanced sarcomas
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necessary in 31% of the proposed trabectedin cycles 
(hematologic toxicities in 16%, alkaline phosphate 
elevation  in  57%  and  bilirubin  elevation  in  27%). 
Grade 3 or 4 leukopenia occurred in 22% and 33% of 
the patients. Grade 3 and 4 AST and ALT elevations 
were also frequent (34 and 36%).23
Interestingly, in a small Italian series of 32 patients 
no severe adverse events were documented with a 
median duration of treatment of 10 months.24
Trabectedin is clinically well tolerated overall. 
Fatigue seems to be the most common subjective 
complaint.  Nausea,  vomiting  and  diarrhea  are 
also  possible,  but  less  frequent  when  compared 
to other drugs used in the treatment of STS. Most 
myelosuppressive  events  are  limited,  with  only 
a  few  patients  developing  severe  neutropenia 
and thrombocytopenia. One of the most common 
laboratory  abnormalities  is  transaminitis.  This 
is  usually  self-limiting  especially  when  treated 
with  dose-reductions.  Clinically  significant  liver 
toxicities  are  uncommon.  There  is  preclinical 
and  clinical  data  for  the  benefits  of  pretreatment 
with  dexamethasone,  which  likely  via  its    anti-
inflammatory  effects  further  decreases  potential 
liver toxicities. The much less frequently reported 
rhabdomyolysis  requires  monitoring  of  serum 
creatine phosphokinase.
Dexamethasone  (typically  20  mg  IV)  is  now 
required  as  premedication  for  trabectedin  cycles, 
with an observed decrease in hepatotoxicity. Whether 
this  is  simply  due  to  an  increased  pharmacologic 
clearance of the drug and therefore a lower effective 
exposure, or whether there is some more liver specific 
mechanism is unknown.
Efficacy
Trabectedin’s efficacy as a chemotherapeutic agent 
has  been  examined  in  randomized  multicenter 
phase II studies (Table 1). An open-label phase II trial 
randomized 270 patients with pretreated LPS or LMS 
after standard therapy failure.19 This trial used time 
to progression as a primary end-point. Patients were 
randomly assigned to 1.5 mg/m2 IV over 24 hours q3 
week versus 0.58 mg/m2 IV over 3 hours each week 3 
of 4 weeks. Cross-over after disease progression was 
allowed. A total of 206 progression events comprised 
the protocol-specified primary efficacy analysis, in 
which median time to progression was 3.7 months 
versus 2.3 months clearly favoring the q3 weeks 24 hr 
arm. Time to progression with trabectedin versus last 
cycle of prior chemotherapy was at least 33% longer 
for  trabectedin  than  prior  chemo  therapy  favoring 
the q3 weeks 24 hour arm (36.7% versus 31.2%). 
Median  progression-free  survival  was  3.3  months 
versus 2.3 months and median overall survival was 
13.0 months versus 11.8 months. Both of these latter 
analyses favored the q3 week 24-hr arm.
Another  EORTC  study  examined  99  assessable 
patients  form  eight  European  institutions  in  a 
phase II study.20 All 99 patients received at least one 
cycle of trabectedin and 30% of patients received at 
least  six  cycles  of  chemotherapy. Amongst  the  99 
treated  patients  there  were  eight  partial  responses, 
45  patients  with  no  change  and  39  patients  with 
Table 1. Summary of prominent phase II clinical trials with trabectedin.
# Pts Dose schedule Response rate;  
pR + cR
Median pFs 
(mos)
Median Os 
(mos)
Death
Demetri et al19  
two arm-randomized trial
136 
134
3 weeks 
24 hr infusion 
1 week  
3 hr infusion
5.6%* 3.3 
 
 
2.3
13.9 
 
 
11.8
3.1% 
 
 
2.3%
Garcia-Carbonero et al**,22 36 3 weeks 
24 hr infusion
8% 1.7 12.1 None
Garcia-Carbonero et al23 35 3 weeks 
24 hr infusion
17% 1.6 15.8 None
Le Cesne et al20 104 3 weeks 
24 hr infusion
8.1% 3.5 9.2 4%
Yovine et al21 54 3 weeks 
24 hr infusion
4% 1.9 12.8 4%
Notes: *ReCIST criteria; **Chemotherapy-naïve patients only.Gajdos and elias
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progressive disease. Survival curves were generated 
based  on  an  intention  to  treat  analysis.  The  one 
year progression-free survival was 17% and overall 
survival  was  42%.  Six  percent  underwent  surgical 
resection  after  preoperative  treatment  and  were 
considered free of disease. The outcome was similar 
in  patients  with  previous  treatment  responsive  or 
resistant tumors. This study also analyzed response in 
various histologic subtypes of STS’s. Partial response 
or no change was seen in 56% of LMS (24/43), 61% of 
synovial sarcomas (11/18), 83% of malignant fibrous 
histiocytomas (5/6), and in 40% of LPS (4/10).
A  multicenter  study  from  French  institutions 
reported treatment results of 52 patients who received 
trabectedin  as  a  second  line  agent  for  advanced 
STS.21 Most patients had LMS (41%) and 24-hour 
continuous iv infusion every 3 weeks was used. There 
were  two  patients  with  partial  response,  four  with 
minor response and nine with stable disease for at 
least 6 months. The median survival was 12.8 months 
with a 2-year overall survival of 30%.
A  phase  II  pharmacokinetic  study  enrolling 
36  previously  pretreated  patients  with  STS  was 
performed using single agent trabectedin as a 24-hour 
continuous  iv  infusion  every  3  weeks.22  Restaging 
was  performed  following  every  two  cycles.  The 
most frequent histological subtypes were LMS, LPS 
and synovial cell sarcoma with lung being the most 
frequent site of metastatic disease. The majority of 
patients (77%) had bulky disease having at least one 
lesion measuring 5 cm or more in longest diameter. 
In  terms  of  response,  three  patients  had  major 
objective response; one complete and two partial. The 
median time to progression and overall survival were 
1.7 months and 12.1 months.
Another phase II study examined the effects of 
trabectedin in 36 chemotherapy-naïve patients.23 The 
drug was administered as a 24 hr continuous infusion 
every 3 weeks. The predominant histologic subtypes 
were LMS and LPS again. The overall response rate 
was 17% with one complete, five partial responses. 
The  1-year  progression-free  and  overall  survival 
rates were 21% and 72%. The authors concluded the 
  trabectedin has promising activity as a first line agent 
with acceptable toxicity.
A recently published French study looked at the effi-
cacy of trabectedin in 92 patients with histologically 
proven,  unresectable  advanced,  or    metastatic  STS 
treated in a single institution.25 Half of the patients 
were  treated  in  phase  II  studies,  the  other  half  on 
compassionate basis. Thirty-two percent of patients 
had LMS or LPS, the rest of the patients had unclas-
sified, osteosarcoma Ewing’s sarcoma or other his-
tologic  subtypes.  The  objective  response  rate  was 
10%. There were no complete responders but overall 
47% had clinical benefit from treatment. The median 
progression-free survival and overall survivals were 
2.2 months and 8.2 months. While initially a higher 
efficacy was observed in phase II studies compared to 
compassionate use program, no significant difference 
remained  after  adjustment  for  performance  status. 
The authors concluded that patients with better per-
formance status derive more benefit from treatment 
with trabectedin.
A small retrospective study from Italy   examined 
the  long-term  effects  of  trabectedin  in  myxoid 
LPS  in  32  patients.24  Trabectedin  was  given  as  a 
24-h  continuous  infusion  every  21  days  with  a 
total  of  376  cycles  administered  (median  of  12/
patient). All patients had previous treatment: 15 had 
chemotherapy, seven had surgery, one had radiation and 
nine had surgery with radiation and/or chemotherapy. 
There were 2 complete responders, 14 patients partial 
response and an objective response rate of 50% was 
reported  by  the  RECIST  criteria.  With  a  median 
follow-up of 24 months, the progression free survival 
was 17 months. Ten patients stopped therapy after a 
median of ten months secondary to absence of evident 
disease (seven had surgery).
Another retrospective study mostly from European 
institutions also examined the efficacy of trabectedin.26 
Fifty-one patients with advanced pretreated myxoid 
LPS treated with trabectedin as a second line agent, 
were analyzed. With a median follow-up of 14 months 
two patients had complete response and 24 patients 
had  partial  response  bringing  the  overall  response 
rate to 51%. The median progression free survival 
was 14 months. Based on these encouraging results 
two prospective studies were initiated to assess the 
role of trabectedin in this subgroup of translocation 
related sarcoma.
A  European  multi-institutional  study  assessed 
the effects of trabectedin treatment in patients with 
advanced  gastrointestinal  stromal  tumors  (GIST). Trabectedin treatment in advanced sarcomas
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Twenty-eight  patients  with  a  median  performance 
status of 0 were enrolled. No objective response was 
seen.  One-third  of  the  patients  had  stable  disease. 
Trabectedin  appears  to  be  an  ineffective  drug  for 
GIST.27
Between  2005  and  2009,  1404  patients  with 
advanced STS were enrolled in an Expanded Access 
Program using trabectedin at 1.5 mg/m2/24 h infusion 
q3 weeks.28 LMS (35%) and LPS (15%) were the 
most common subgroups. Most had prior treatment 
with anthracycline and ifosfamide (median 3 lines 
of therapy). More than 6 cycles were given to 30%, 
and  median  dose  intensity  was  1.3  mg/m2/cycle. 
Most common reasons for dose adjustments included 
dose  delay  for  neutropenia,  and  dose  decrease  for 
transaminitis or increased alkaline phosphatase. Severe 
elevation of CPK was less common. Of 504 evaluable 
patients, 8% had complete or partial response, 33% 
had stable disease, and progression occurred in 45% 
of patients.
Patient preference
In  phase  I  studies  trabectedin  showed  cytotoxic 
potential  in  patients  with  advanced  STS,  breast 
cancer, ovarian cancer and other types of solid tumors. 
Trials have reported its use as a single agent or in 
conjunction with another agent, such as doxorubicin, 
docetaxel,  gemcitobine,  carboplatin.  The  currently 
available preclinical and clinical evidence suggests, 
that trabectedin is best used as a second line agent 
in metastatic/recurrent LPS and LMS with favorable 
response rates compared to traditionally used drugs.
Since trabectedin has consistently shown hepatox-
icity and hematologic side effects in various studies, 
patients with alcohol abuse, underlying liver disease/
elevated bilirubin or hematologic abnormalities may 
not be the best candidates for this drug. The pharma-
cokinetics  of  trabectedin  have  not  been  studied  in 
patients with hepatic impairment. On the other hand, 
renal impairment does not seem to be a contraindication 
to its use in patients with underlying mild to moderate 
renal disease.6 There is also some published evidence 
for its use in elderly patients with compromised per-
formance status without significant additional risks.6 
On the other hand, a retrospective review from France 
found 0–1 performance status patients benefiting the 
most form treatment with trabectedin.25
There is some data for trabectedin being used in 
the  neoadjuvant  setting  in  locally  advanced,  non-
metastatic  patients  with  favorable  response  rates 
compared to standard chemotherapeutic agents tradi-
tionally used in the same setting.29
Place in therapy: Food and Drug 
Administration (FDA) and european 
Status
A phase III trial of pegylated liposomal doxorubicin 
(PLD) with or without trabectedin was performed in 
672 women with recurrent ovarian cancer.30 The com-
bination  was  superior  for  median  progression  free 
survival (7.3 vs. 5.8 months, HR 0.79, P = 0.017), 
for response rate (27.6% vs. 18.8%, P = 0.008), but 
not for overall survival (20.5 vs. 19.4 months, HR 
0.95, P = 0.15). Platinum-sensitive patients appeared 
to derive greater benefit. The combination had more 
neutropenia,  transient  transaminitis,  but  less  hand 
foot syndrome (HFS) and mucositis. This trial led to 
European accelerated approval in cisplatin-sensitive 
ovarian cancer.
Trabectedin is approved in the European Union 
and some other countries as a second-line treatment 
for advanced STS based on the clinical benefit rates 
documented in phase II trials. The FDA, however, 
recently disapproved accelerated approval, because 
of hepatotoxicity and a lack of documented survival 
advantage. With  phase  III  studies  on  the  way,  the 
  current evidence for its efficacy may provide enough 
data for the FDA for an approval in the treatment of 
STS in previously pretreated patients.
Current randomized trials of trabectedin in sar-
comas are listed in the Table 2. Each has a unique 
design. The Spanish trial (phase II) is examining the 
value of adding trabectedin to doxorubicin in first 
line  metastatic  treatment.  The  EORTC  is  testing 
the  comparison  of  doxorubicin  versus  trabectedin 
in  the  same    population.  Two  trials  sponsored  by 
Pharma Mar (Tres Cantos, Madrid, Spain) include a 
doxorubicin-  containing regimen versus trabectedin 
in translocation-related sarcomas and a comparison 
to dacarbazine in LMS and LPS. This latter study, 
the  design  of  which  is  still  under  negotiation  at 
the FDA, will look at OS as the primary endpoint 
and  therefore  no  crossover  to  trabectedin  will  be 
allowed.Gajdos and elias
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Conclusions
Various  trabectedin  regimens  demonstrated  signifi-
cant antitumor activity in patients with LPS or LMS 
after  failure  of  treatment  with  currently  available 
approved (anthracyclines and ifosfamides) and non-
approved drugs (gemcitabine, docetaxel). In addition, 
the   overall survival rates of over 10 months with tra-
bectedin therapy are also significantly better than the 
published results of 6 months with standard therapy 
for advanced/metastatic STS. In general,   trabectedin 
is well tolerated with comparable toxicity profile to 
standard treatments. Transient, noncumulative hepatic 
toxicity is usually self-limiting and can be pretreated 
with steroids. Trabectedin can be safely used in patients 
with STS especially in LPS and LMS with improved 
progression free and overall survival.   Trabectedin is 
one the most promising cytotoxic agents tested in the 
last two decades. This drug is becoming an impor-
tant  therapeutic  option  for  patients  who  exhausted 
anthracycline/ifosfamide treatments with progression 
of their disease. Trabectedin also has the potential 
for becoming a front-line treatment for patients with 
advanced/metastatic STS.
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